# Fervor over top-selling drugs fuels biotech dealmaking — retained record

> Retained news record from news:semafor.

Canonical: https://highsignal.app/data/records/9e07a8d3a220027f

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:semafor)  published 2026-07-21 23:16 ingested 2026-07-22 08:34

[original source ↗](https://www.semafor.com/article/07/21/2026/fervor-over-top-selling-drugs-fuels-biotech-dealmaking)

## retained text



```
Biotech is commanding attention from dealmakers and investors. Pharma companies have acquired 37 biotech firms worth at least $1 billion this year, more than all of 2025, as they race to bolster pipelines before several blockbuster drugs lose their patent protections in the coming years.
The Trump administration’s light-touch regulatory approach and windfalls from top-selling drugs are also driving M&A, the Financial Times noted.
Against this backdrop, biotech and pharma firms’ IPOs are producing some of the year’s strongest returns, outperforming many AI-related listings, Bloomberg reported. “This is the healthiest biotech IPO market we have had in a long time,” an investment banker said.
```



document fetched 2026-07-22 08:34 · canonical https://semafor.com/article/07/21/2026/fervor-over-top-selling-drugs-fuels-biotech-dealmaking